Business
Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference
SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC) will be presented at the \"AI and Big Data in Cancer: From Innovation to Impact\" conference. Cchek™ is Anixa's artificial intelligence (AI) driven cancer detection technology. \n\n \n \n\n \nThe \"AI and Big Data in Cancer\" conference takes place March 29-31, 2020 at the Westin Boston Waterfront in Boston, Massachusetts and is designed to accelerate the implementation of AI in oncology care. The conference will showcase the impact the technology has had on diagnosis, treatment decisions and patient care and illustrate how technology, data and analytics innovations can be translated into clinical practices. The meeting will be attended by researchers, academics, clinicians, technologists, entrepreneurs, regulators and insurance payers. \nDetails of the presentation are as follows:\nAbstract title: Using artificial intelligence to detect prostate cancer – how a flow cytometry-based liquid biopsy assay can help reduce the number of unnecessary prostate biopsies performed each yearAuthors: George Dominguez, PhD, John Roop, Anthony Campisi, Amit Kumar, PhDPresenting Author: George Dominguez, PhDPoster Number: P.14Room: Grand Ballroom C,D,EPresentation Dates and Times: Sunday, March 29, 2020 (6:00 PM – 7:00 PM) Monday, March 30, 2020 (1:00 PM – 2:00 PM) Tuesday, March 31, 2020 (1:00 PM – 2:00 PM)\nAbout Cchek™Cchek™ is an early cancer detection technology, that measures a patient's immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa's orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek™ to detect the presence of 20 different cancers i...